Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Equity: €686.7 Mil (As of Mar. 2026)


XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
93 GF Score
Price €56.90
GF Value €50.99
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Total Equity?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -0.87% 93 Total Equity is €686.7 Mil as of Mar. 2026. GuruFocus rates XMAD:ROVI with a GF Score™ of 93/100 and a GF Value™ of €50.99 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Laboratorios Farmaceuticos Rovi's total equity for the quarter that ended in Mar. 2026 was €686.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Laboratorios Farmaceuticos Rovi Total Equity Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Total Equity Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 470.98 521.38 543.49 581.54 675.46

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 599.47 574.72 632.80 675.46 686.73
XMAD:ROVI
93GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Laboratorios Farmaceuticos Rovi's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=955.691-280.236
=675.5

Laboratorios Farmaceuticos Rovi's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=926.315-239.584
=686.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €686.7 Mil mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Total Equity of €686.7 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Total Equity too high?
Laboratorios Farmaceuticos Rovi's current Total Equity is €686.7 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Total Equity compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Total Equity of €686.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Total Equity is €686.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.99, compared to a current price of €56.90 — trading 11.6% above its estimated fair value. The current Total Equity is €686.7 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Total Equity is €686.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €56.90 is trading 11.6% above its estimated GF Value™ of €50.99. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for XMAD:ROVI:

  • Total Equity: €686.7 Mil
  • GF Value™: €50.99 vs. price of €56.90 (11.6% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for XMAD:ROVI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.90
Price
€50.99
GF Value